Literature DB >> 8479525

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.

J D Oliner1, J A Pietenpol, S Thiagalingam, J Gyuris, K W Kinzler, B Vogelstein.   

Abstract

The tumour-suppressor gene p53 is inactivated in most human malignancies either by missense mutations or by binding to oncogenic proteins. In human soft tissue sarcomas, inactivation apparently results from MDM2 gene amplification. MDM2 is an oncogene product that may function by binding to p53 and inhibiting its ability to activate transcription. Here we show that, when expressed in Saccharomyces cerevisiae, human MDM2 inhibits human p53's ability to stimulate transcription by binding to a region that nearly coincides with the p53 acidic activation domain. The isolated p53 activation domain fused to another DNA-binding protein is also inactivated by MDM2, confirming that MDM2 can inhibit p53 function by concealing the activation domain of p53 from the cellular transcription machinery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8479525     DOI: 10.1038/362857a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  448 in total

Review 1.  The complexity of radiation stress responses: analysis by informatics and functional genomics approaches.

Authors:  A J Fornace; S A Amundson; M Bittner; T G Myers; P Meltzer; J N Weinsten; J Trent
Journal:  Gene Expr       Date:  1999

2.  Choosing anticancer drug targets in the postgenomic era.

Authors:  W G Kaelin
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

3.  Isolation and characterization of a human hepatic epithelial-like cell line (AKN-1) from a normal liver.

Authors:  A K Nussler; G Vergani; S M Gollin; K Dorko; S M Morris; A J Demetris; M Nomoto; H G Beger; S C Strom
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-04       Impact factor: 2.416

Review 4.  Cell cycle checkpoints as therapeutic targets.

Authors:  Z A Stewart; J A Pietenpol
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

5.  Identification of a sequence element from p53 that signals for Mdm2-targeted degradation.

Authors:  J Gu; D Chen; J Rosenblum; R M Rubin; Z M Yuan
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

6.  MdmX protects p53 from Mdm2-mediated degradation.

Authors:  M W Jackson; S J Berberich
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

7.  pRB induces Sp1 activity by relieving inhibition mediated by MDM2.

Authors:  T Johnson-Pais; C Degnin; M J Thayer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

8.  Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300.

Authors:  M J O'Connor; H Zimmermann; S Nielsen; H U Bernard; T Kouzarides
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

9.  A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.

Authors:  J M Stommel; N D Marchenko; G S Jimenez; U M Moll; T J Hope; G M Wahl
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

10.  Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable.

Authors:  L McKendrick; D Milne; D Meek
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.